Callan Capital LLC Sells 1,097 Shares of Novo Nordisk A/S (NYSE:NVO)

Callan Capital LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 25,319 shares of the company’s stock after selling 1,097 shares during the period. Callan Capital LLC’s holdings in Novo Nordisk A/S were worth $2,178,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Indie Asset Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after acquiring an additional 126 shares during the last quarter. Dividend Assets Capital LLC increased its stake in Novo Nordisk A/S by 3.1% in the 4th quarter. Dividend Assets Capital LLC now owns 214,615 shares of the company’s stock worth $18,461,000 after purchasing an additional 6,395 shares during the period. Outfitter Financial LLC boosted its stake in shares of Novo Nordisk A/S by 9.9% during the fourth quarter. Outfitter Financial LLC now owns 8,795 shares of the company’s stock valued at $757,000 after purchasing an additional 795 shares during the period. Bank of Stockton grew its holdings in shares of Novo Nordisk A/S by 6.5% in the fourth quarter. Bank of Stockton now owns 8,151 shares of the company’s stock worth $701,000 after purchasing an additional 499 shares during the last quarter. Finally, Arcadia Investment Management Corp MI boosted its position in Novo Nordisk A/S by 29.8% during the 4th quarter. Arcadia Investment Management Corp MI now owns 4,354 shares of the company’s stock valued at $375,000 after buying an additional 1,000 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $88.07 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a fifty day moving average of $86.01 and a two-hundred day moving average of $108.22. The stock has a market capitalization of $395.19 billion, a PE ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $77.82 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.